SecBot SecBot
8-K ·Filed Nov 10, 2026

PDSB

PDS Biotechnology Corp
NEUTRAL
Impact 4/10
Horizonweeks Processed6d 18h ago SEC0001140361-26-042898
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The warrant exercise provides near-term cash but adds roughly 17.7 million shares to the float, diluting existing holders. Monitor the company's cash runway and progress toward the PDS0301 Phase 3 trial initiation, as the $3.9 million combined with the September 2026 private placement proceeds will fund development.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

PDSB drug pipeline →

PDS0301

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
Next catalyst
None dated

What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.03
T+0 close · Nov 10, 2026 · via day close
Latest settled
−0.97%
T+1 · $1.02
Vs SPY
−2.29%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $1.03entry
  2. T+1 · 6d ago −0.97%α −2.29% · $1.02
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology announced that NantWorks exercised warrants for 17,699,115 shares at $0.22 per share, generating approximately $3.9 million in gross proceeds. The warrants were issued in connection with a September 2026 private placement that raised $11.3 million. Proceeds will fund advancement of PDS0301 toward a Phase 3 trial and partnership strategy for PDS0101.

Key Facts

  • NantWorks exercised warrants to purchase 17,699,115 shares at $0.22 per share
  • Gross proceeds to PDS Biotechnology were approximately $3.9 million
  • Warrants were issued in connection with a September 14, 2026 private placement that raised $11.3 million
  • Proceeds will support advancement of PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and partnership strategy for PDS0101
  • Warrants are subject to a 19.9% beneficial ownership limitation; excess exercised for pre-funded warrants at $0.00033 per share
  • Company market cap is $129 million; the 17.7 million shares represent significant dilution relative to current shares outstanding

Financial Impact

Gross proceeds of approximately $3.9 million from warrant exercise; 17,699,115 shares issued at $0.22 per share

dilutioncash

Risk Factors

  • Significant dilution from the issuance of 17.7 million shares at a low exercise price
  • Clinical-stage biotech with no approved products; reliance on additional financing to fund operations
  • Proceeds may be insufficient to fully fund Phase 3 trial for PDS0301

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-042898
Document: ef20085268_ex99-1.htm0001140361-26-042898
Document: 0001140361-26-042898-index-headers.html0001140361-26-042898
Document: 0001140361-26-042898-index.html0001140361-26-042898
Document: 0001140361-26-042898.txt0001140361-26-042898

Track record

28 reports on PDSB

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026